Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Target Cut by Wedbush

Posted by Francis Steltz on Oct 27th, 2026

Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) had its price target decreased by Wedbush from $17.00 to $14.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush‘s price target points to a potential upside of 55.47% from the stock’s current price.

Other research analysts also recently issued reports about the company. BTIG Research initiated coverage on Oric Pharmaceuticals in a research note on Wednesday, September 23rd. They set a “buy” rating and a $26.00 target price for the company. JPMorgan Chase & Co. increased their price target on Oric Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Wall Street Zen raised Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, July 25th. Leerink Partners began coverage on Oric Pharmaceuticals in a report on Monday, October 5th. They set an “outperform” rating and a $26.00 price target for the company. Finally, HC Wainwright lifted their price objective on shares of Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Fourteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Oric Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $21.25.

Get Our Latest Analysis on Oric Pharmaceuticals

Oric Pharmaceuticals Price Performance

Oric Pharmaceuticals stock opened at $9.01 on Tuesday. The company’s 50-day moving average is $12.85 and its 200-day moving average is $11.14. The firm has a market capitalization of $933.37 million, a PE ratio of -6.71 and a beta of 0.99. Oric Pharmaceuticals has a fifty-two week low of $7.23 and a fifty-two week high of $14.68.

Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.02). As a group, analysts expect that Oric Pharmaceuticals will post -1.53 EPS for the current year.

Insider Activity

In other news, CFO Dominic Piscitelli sold 14,000 shares of the business’s stock in a transaction dated Tuesday, October 20th. The shares were sold at an average price of $13.53, for a total value of $189,420.00. Following the completion of the sale, the chief financial officer owned 69,828 shares of the company’s stock, valued at approximately $944,772.84. The trade was a 16.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 105,000 shares of company stock valued at $1,432,952 over the last three months. Insiders own 5.70% of the company’s stock.

Institutional Trading of Oric Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in Oric Pharmaceuticals in the 2nd quarter valued at about $73,904,000. Siren L.L.C. increased its holdings in shares of Oric Pharmaceuticals by 197.6% during the first quarter. Siren L.L.C. now owns 2,998,192 shares of the company’s stock worth $37,987,000 after purchasing an additional 1,990,617 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Oric Pharmaceuticals by 19.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,471,290 shares of the company’s stock valued at $18,637,000 after buying an additional 244,060 shares in the last quarter. Algert Global LLC raised its position in shares of Oric Pharmaceuticals by 791.3% in the second quarter. Algert Global LLC now owns 1,215,293 shares of the company’s stock valued at $13,162,000 after buying an additional 1,078,943 shares in the last quarter. Finally, Braidwell LP raised its position in shares of Oric Pharmaceuticals by 7.7% in the second quarter. Braidwell LP now owns 1,214,540 shares of the company’s stock valued at $13,153,000 after buying an additional 86,500 shares in the last quarter. Institutional investors and hedge funds own 95.05% of the company’s stock.

About Oric Pharmaceuticals

(Get Free Report)

Oric Pharmaceuticals, Inc (NASDAQ: ORIC) is a clinical-stage biopharmaceutical company focused on developing medicines that overcome mechanisms of treatment resistance in cancer. The company uses its discovery platform to identify therapies intended to improve or restore the effectiveness of existing cancer treatments.

Oric’s pipeline has included ORIC-533, an oral small-molecule inhibitor of CD73 designed to block adenosine-mediated immunosuppression in the tumor microenvironment. The company has evaluated the program in hematologic malignancies, including multiple myeloma.